The HIT treatment in a cardiac surgery patient

• Published in: International journal of cardiology 2010-10, Vol.144 (3), p.405-407
• Main Authors: Anna, Neykova, Boyan, Tzvetkov, Kader, Merah Abdel, Catherine, Matheron, Matthias, Kirsch
• Format: Article
• Language: English
• Subjects: Anticoagulants - administration & dosage; Anticoagulants - adverse effects; Biological and medical sciences; Cardiac surgery; Cardiology. Vascular system; Cardiovascular; Coronary Artery Bypass - adverse effects; Coronary Artery Disease - complications; Coronary Artery Disease - therapy; Diabetes Mellitus, Type 1 - complications; Drug Therapy, Combination; Fondaparinux; Hematologic and hematopoietic diseases; Heparin - administration & dosage; Heparin - adverse effects; Heparin-induced thrombocytopenia; Humans; Male; Medical sciences; Middle Aged; Platelet Count; Platelet diseases and coagulopathies; Polysaccharides - administration & dosage; Polysaccharides - therapeutic use; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases; Surgery of the heart; Thrombocytopenia - chemically induced; Thrombocytopenia - diagnosis; Thrombocytopenia - drug therapy; Treatment Outcome
• ISSN: 0167-5273; 1874-1754
• DOI: 10.1016/j.ijcard.2009.03.027

Abstract Heparin-induced thrombocytopenia (HIT) occurs in 1 to 3% of patients after cardiac surgery. In patients with suspected or confirmed HIT, the standard of care is withheld of heparin, and an alternative, non-heparin anticoagulant substituted. An established fact is that currently only direct thrombin inhibitors (lepirudin, bivalirudin and argatroban) and heparinoids like danaparoid are approved for alternative anticoagulation in HIT patients. Herein, we report the case of a patient who developed HIT after coronary artery bypass grafting (CABG) and who was successfully treated by the factor Xa inhibitor fondaparinux. Danaparoid is our first line alternative anticoagulant to treat HIT patients. Normally the recovery from thrombocytopenia began within 24 h. In the present patient, however, platelet counts continued to fall for 3 more days. Discontinuation of danaparoid and anticoagulation with fondaparinux clearly improved platelet counts which normalized. The present patient has been treated for 26 consecutive days, and we have not observed any subsequent fall in platelet counts and any further bleeding or thrombotic complications.